PDCD1LG2
PDCD1LG2 (Programmed cell death 1 ligand 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and an antigen, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma, Thyroid cancer, Breast cancer and 2 more.
Overview
Plays a critical role in induction and maintenance of immune tolerance to self. Acts as a ligand for the inhibitory receptor PDCD1/PD-1, inhibiting T-cell proliferation by blocking cell cycle progression and cytokine production.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Pembrolizumab. Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.00, somatic mutation 0.82). IntOGen calls it a driver in 2 cohorts (2 activating, 0 loss-of-function), covering Melanoma, Well-Differentiated Thyroid Cancer. In OnCo, 3 product records name it (Retifanlimab, Sintilimab and Sasanlimab).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PDCD1LG2 (Programmed cell death 1 ligand 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and an antigen, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma, Thyroid cancer, Breast cancer and 2 more.
- 1 · What it is
PDCD1LG2 (Programmed cell death 1 ligand 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and an antigen, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma, Thyroid cancer, Breast cancer and 2 more.
- 2 · What goes wrong in cancer
Plays a critical role in induction and maintenance of immune tolerance to self. Acts as a ligand for the inhibitory receptor PDCD1/PD-1, inhibiting T-cell proliferation by blocking cell cycle progression and cytokine production.
- 3 · How drugs use it
No product in this corpus aims at PDCD1LG2 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:18731 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9BQ51 (protein name, function text, keywords and locations (REST API)); CIViC gene PDCD1LG2 (1 evidence items, 0 assertions, 1 variants; diseases: Head And Neck Cancer (GraphQL API, CC0)); Open Targets ENSG00000197646 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: breast cancer 0.54 (GraphQL API, CC0)); IntOGen PDCD1LG2 (driver in 2 cohorts (Act 2, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Plays a critical role in induction and maintenance of immune tolerance to self. Acts as a ligand for the inhibitory receptor PDCD1/PD-1, inhibiting T-cell proliferation by blocking cell cycle progression and cytokine production. Location: Secreted; Endomembrane system; Cell membrane (UniProt). Locus 9p24.1 (HGNC).
- Head and neck squamous cell carcinoma: CIViC evidence names this disease
- Thyroid cancer: IntOGen driver in 1 cohort (WDTC)
- Breast cancer: Open Targets association 0.54 with breast cancer (MONDO_0007254)
- Melanoma: IntOGen driver in 1 cohort (MEL)
- Papillary thyroid cancer: IntOGen driver in 1 cohort (WDTC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants; a membrane or secreted protein (UniProt keywords) that 3 antibody-based OnCo products name. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PDCD1LG2" OR ABSTRACT:"PDCD1LG2" OR TITLE:"programmed cell death 1 ligand 2" OR ABSTRACT:"programmed cell death 1 ligand 2" OR TITLE:"Programmed cell death 1 ligand 2" OR ABSTRACT:"Programmed cell death 1 ligand 2" OR TITLE:"PD-L2" OR ABSTRACT:"PD-L2" OR TITLE:"Btdc" OR ABSTRACT:"Btdc" OR TITLE:"PDL2" OR ABSTRACT:"PDL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PDCD1LG2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetEIF1AX
Shares Papillary thyroid cancer, Thyroid cancer, CIViC, IntOGen.
- TargetSMAD3
Shares Thyroid cancer, Breast cancer (all types), CIViC, IntOGen.
- TargetAFF3
Shares Papillary thyroid cancer, Thyroid cancer, Breast cancer (all types), IntOGen.
- TargetCDKN1B
Shares Thyroid cancer, Breast cancer (all types), CIViC, IntOGen.
- TargetCOL2A1
Shares Papillary thyroid cancer, Thyroid cancer, IntOGen.
- TargetPICALM
Shares Papillary thyroid cancer, Thyroid cancer, IntOGen.
- TargetFAM135B
Shares Papillary thyroid cancer, Thyroid cancer, IntOGen, Head and neck squamous cell carcinoma.
- TargetHRAS
Shares Thyroid cancer, Breast cancer (all types), CIViC, IntOGen.